Healthcare -
Biotechnology - NASDAQ - US
$ 0.0266
1.14 %
$ 247 K
Market Cap
0.09
P/E
1. INTRINSIC VALUE
Balance Sheet
SAB Biotherapeutics, Inc.
| Current Assets | 23.8 M |
| Cash & Short-Term Investments | 20.8 M |
| Receivables | 55 K |
| Other Current Assets | 2.98 M |
| Non-Current Assets | 20.4 M |
| Long-Term Investments | 0 |
| PP&E | 19.9 M |
| Other Non-Current Assets | 482 K |
| Current Liabilities | 7.98 M |
| Accounts Payable | 1.69 M |
| Short-Term Debt | 812 K |
| Other Current Liabilities | 5.47 M |
| Non-Current Liabilities | 10.2 M |
| Long-Term Debt | 3.86 M |
| Other Non-Current Liabilities | 6.39 M |
EFFICIENCY
Earnings Waterfall
SAB Biotherapeutics, Inc.
| Revenue | 1.32 M |
| Cost Of Revenue | 0 |
| Gross Profit | 1.32 M |
| Operating Expenses | 44.2 M |
| Operating Income | -42.9 M |
| Other Expenses | -8.81 M |
| Net Income | -34.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
SAB Biotherapeutics, Inc.
| Net Income | -34.1 M |
| Depreciation & Amortization | 4.79 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 2.94 M |
| Change in Working Capital | -2.3 M |
| Others | -8.84 M |
| Free Cash Flow | -34.3 M |
Wall Street Analysts Price Targets
SAB Biotherapeutics, Inc.
SABSW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
SABSW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
SAB Biotherapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
8. Profile
Summary
SAB Biotherapeutics, Inc. SABSW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 247 K
Dividend Yield
0.00%
Description
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
Contact
2100 East 54th Street North, Sioux Falls, SD, 33140
http://www.sabbiotherapeutics.com
IPO
Date
Oct. 25, 2021
Employees
63
Officers
Dr. Christoph Bausch M.B.A., Ph.D.
Executive Vice President & Chief Operating Officer
Dr. Alexandra Kropotova M.B.A., M.D.
Executive Vice President & Chief Medical Officer
Mr. Samuel J. Reich
Chief Executive Officer & Executive Chairman
Ms. Lucy To
Executive Vice President & Chief Financial Officer
Dr. Carlos N. Carillo Ph.D.
Senior Vice President of Regulatory Affairs
Dr. Edward D. Hamilton D.V.M.
Co-Founder & Board Observer
Ms. Christine E. Hamilton M.B.A.
Co-Founder & Independent Director
Dr. Eddie Joe Sullivan Ph.D.
Co-Founder, President & Director